Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib

The development of highly effective targeted therapies has led to a new treatment paradigm in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Despite these advances, many patients will eventually require alternative treatment strategies due to the emergence of tol...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Ankit, Barrientos, Jacqueline C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006759/
https://www.ncbi.nlm.nih.gov/pubmed/33790574
http://dx.doi.org/10.2147/OTT.S189032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006759/
https://www.ncbi.nlm.nih.gov/pubmed/33790574
http://dx.doi.org/10.2147/OTT.S189032

Ejemplares similares